The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
Yasuhide Yamada
Honoraria - Chugai Pharma; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca; Bayer; Eisai; Merck; Novartis
Hiroshi Nokihara
Research Funding - Chugai Pharma; Eisai; Merck; Pfizer
Noboru Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Pfizer; Takeda
Yutaka Fujiwara
No relevant relationships to disclose
Yosuke Tamura
No relevant relationships to disclose
Hiroshi Wakui
No relevant relationships to disclose
Kazunori Honda
No relevant relationships to disclose
Shinji Nakamichi
No relevant relationships to disclose
Hajime Asahina
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - Pfizer
Other Remuneration - AstraZeneca
Yuko Tanabe
Other Remuneration - Merck
Satoru Kitazono
No relevant relationships to disclose
Hidenori Mizugaki
No relevant relationships to disclose
Naoya Yamazaki
Honoraria - Chugai Pharma
Shigenobu Suzuki
No relevant relationships to disclose
Junichi Sasaki
No relevant relationships to disclose
Mieko Matsuoka
Employment or Leadership Position - Chugai Pharma
Tomohide Tamura
Honoraria - AstraZeneca; Chugai Pharma; Novartis; Pfizer
Research Funding - Chugai Pharma; Eisai; GlaxoSmithKline